Company profile
Neurogenesis, Inc.
OTC: NEUN · Healthcare · Medical - Pharmaceuticals
#949 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
——FH —DQ —GM —SS 60
v0.1 · 5/100 weight · pillars only
↑ return on assets, listing tenure · ↓ market scale, disclosure history
Methodology →Revenue TTM
$399.2k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$15.6k
Employees
307
as of 2026-08-03
Market cap
$8.2k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$399.2k$399.2k2013
Net income$15.6k$15.6k2013
Operating income$32.9k$32.9k2013
Total assets$87.7k$87.7k2013
Liabilities$193.4k$193.4k2013
Equity-$105.7k-$105.7k2013
Revenue trend
FY2011 – FY2013 · USD
FY11
FY12
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Neurogenesis, Inc.’s revenue?
Neurogenesis, Inc. booked $399.2k in FY2013 revenue, contracting 15% year over year — slower than 70% of Healthcare companies we track, at a 3.9% net margin.
Peers · Healthcare
MediciNova, Inc.41DCartesian Therapeutics, Inc.40DiBio, Inc.49DLyra Therapeutics, Inc.30DOMID Holdings, Inc.48DAmerica Great Health39DNeighbors
Galveston →Key facts
CEOKeith J. Sullivan
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersLeague City, TX
ExchangeOTC: NEUN
Employees307
IPO date1998-06-05
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.